Comparison 2. Serlopitant 1 mg versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Patient‐reported pruritus intensity VAS (dichotomous)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2 Patient‐reported pruritus intensity VAS (continuous)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3 Patient‐reported pruritus intensity NRS (dichotomous)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4 Patient‐reported pruritus intensity NRS (continuous)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
5 Patient‐reported pruritus intensity VAS (continuous) ‐ 10 weeks	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6 Adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
7 Health‐related quality of life	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
8 Health‐related quality of life ‐ 10 weeks	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
9 Sleep disturbance	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected